PERSONAL INFORMATION

Paolo Caliceti

Affiliation
University of Padova
Pharmaceutical and Pharmacological Sciences
Via F. Marzolo 5 -35131 Padova - Italy

+39 049 8275695 +39 349 7499602

paolo.caliceti@unipd.it

State personal website(s)

Sex Male | *Date of birth* 29.05.1959 | *Nationality* Italy

Enterprise	University	EPR
☐ Management Level	☒ Full professor	☐ Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
☐ Mid-Management Level	☐ Associate Professor	☐ Level III Researcher and Technologist
☐ Employee / worker level	☐ Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	☐ Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

01.04.2001-current

Full Professor

University of Padova
- Teaching and Research (pharmaceutical nanotechnology, advanced, stimuli sensitive, drug delivery and targeting)

Pharmaceutical Technology and Advanced Drug Delivery

01.10.1998-31.03.2001

Associate Professor

University of Padova
- Teaching and Research (pharmaceutical nanotechnology, advanced, stimuli sensitive, drug delivery, targeting)

Pharmaceutical Technology and Drug Delivery

20.11.1989-10.09.1998

Assistant Professor

University of Padova
- Teaching and Research (bioconjugation, therapeutic protein PEGylation, biocompatible polymers)

Pharmaceutical Technology and Advanced Drug Delivery

EDUCATION AND TRAINING

1985-1989

PhD in Pharmaceutical Sciences

Replace with EQF (or other) level if relevant

University of Padova - Italy
Drug delivery: protein PEGylation

1978-1984

Master of Science in Pharmaceutical Chemistry and Technology

University of Padova - Italy
Biochemistry: protein structure characterization

WORK ACTIVITIES

20.02.1994 - 20.08.1994 Invited Scientist – Smithkline and Beecham– King of Prussia, United States
01.02.1990 - 30.03.1990 Invited Scientist – Academy of Sciences – Moscow, Russia
01.07.1986 - 10.01.1987 Invited Scientist – NIH– Bethesda, United States
01.10.2015 - 30.09.2019 Head of the Department of Pharmaceutical and Pharmacological Sciences
01.10.2002 - 30.09.2006 Vice-head of Department of Pharmaceutical Sciences
01.01.2009 - 31.12.2014 President of Controlled Release Society Italy Chapter
01.01.2021-current President of Division of Pharmaceutical Technology - Italian Chemical Society
01.01.2021-current President of ADRITELF – Italian Ass. of Pharmaceutical Legislation and Technology
Consultant with national and multinational pharmaceutical companies
Evaluator for granting: EU agencies (IMI and ERC) and foreign Scientific Institutions

Editorial activity Associate editor of Journal of Controlled Release
Editorial board member of Journal of Drug Delivery Science and Technology
Editorial board member of other pharmaceutical journals

Invited presentations Over 50

Grants Last grant ITN-MSC OCUTHER

Patents 15

ADDITIONAL INFORMATION

Publications Number of total publications in peer-review journals 175, in the last ten years (2013-2022): 56
Impact Factor (2020 journal IF wos) of the total papers of last ten years: 320.08
Average IF/paper of the last ten years : 6.4
Total number of citations: 7233
H index: 48

1. Brunato, S., et al. *Thermosensitive "Smart" Surfaces for Biorecognition Based Cell Adhesion and Controlled Detachment.* Macromol. Biosci. (2021) 21(2):e2000277 doi: 10.1002/mabi.202000277.

2. Brunato S. et al. *PEG-polyaminoacid based micelles for controlled release of doxorubicin: Rational design, safety and efficacy study*. J Control. Release (2021) 335:21-37. doi: 10.1016/j.jconrel.2021.05.010.

3. Mastrotto F., et al. *In Vitro and in Vivo Behavior of Liposomes Decorated with PEGs with Different Chemical Features* Mol. Pharm. (2020) 17, (2) 472-487. doi.org/10.1021/acs.molpharmaceut.9b00887

4. Malfanti Aet al. S. *Oligo-guanidyl targeted bioconjugates forming rod shaped polyplexes as a new nanoplatform for oligonucleotide delivery*, J. Control. Release (2019) 310, 58-73. doi.org/10.1016/j.jconrel.2019.08.005

5 Malfanti A., et al. *Novel Oligo-Guanidyl-PEG Carrier Forming Rod-Shaped Polyplexes*. Mol. Pharm. (2019) 16:1678-1693. doi: 10.1021/acs.molpharmaceut.9b00014

6. Brazzale C., et al. *Control of targeting ligand display by pH-responsive polymers on gold nanoparticles mediates selective entry into cancer cells*. Nanoscale (2017) 9 (31):11137-11147. doi: 10.1039/c7nr02595e

7. Scomparin A., et al. *A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index*. J. Control. Release (2015) 208, 106-120. doi:10.1016/j.jconrel.2015.04.009

8. Bonzi G., et al. *Novel pullulan bioconjugate for selective breast cancer bone metastases treatment. bioconjugate chemistry*. Bioconjugate Chem. (2015) 26, 489-501. doi: 10.1021/bc500614b.

9. Salmaso Set al. *A novel soluble supramolecular system for sustained rh-GH delivery.* J. Control. Release (2014) 194, 168-177. doi:10.1016/j.jconrel.2014.08.024.

10. Scaramuzza S., et al. *A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: production and physicochemical characterization*. J. Control. Release, (2012) 154:355-363. doi: 10.1016/j.jconrel.2012.06.026.

09.05-2023 Paolo Caliceti